Other Events ·
Odyssey Therapeutics, Inc. filed a Form 8-K on September 8, 2026, to furnish Exhibit 99.1, a corporate presentation…
ODTXOdyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. filed a Form 8-K on September 8, 2026, to furnish Exhibit 99.1, a corporate presentation posted on its investor website. The presentation details the company's pipeline of oral therapies for inflammatory and autoimmune diseases, including OD-001 (RIPK2 inhibitor) for ulcerative colitis and Crohn’s disease, OD-002 (SLC15A4 inhibitor) for cutaneous lupus erythematosus, and OD-003 (TNFR2 agonist). It reports $433 million in cash as of June 30, 2026, with an expected funding runway into the second half of 2028. The filing outlines clinical milestones such as updated monotherapy data for OD-001 at UEG Week in October 2026 and a CTA filing for OD-002 in H2 2026. Odyssey Therapeutics, Inc. operates in the biotechnology industry, developing small molecule and protein therapies targeting inflammatory and autoimmune diseases.